Galenea Awarded $3 Million National Institutes of Health (NIH) Grant to Develop Translational EEG Biomarkers for Schizophrenia
Published: Sep 06, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers at Galenea Corp., and collaborator Kevin Spencer of the VA Boston Healthcare System and Harvard Medical School, have been awarded a 5-year, $3M grant from the National Institute of Mental Health (NIMH). The grant will fund the development of new biomarkers based on brain wave oscillations in animal models of psychosis and in human schizophrenia patients. The program will incorporate Galenea’s sophisticated in vivo electroencephalography (EEG) technology alongside Dr. Spencer’s innovations in clinical EEG measures.